<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.malariajournal.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Malaria Journal - Latest Articles</title>
        <link>http://www.malariajournal.com</link>
        <description>The latest research articles published by Malaria Journal</description>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/42" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/41" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/40" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/39" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/38" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/37" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/36" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/35" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/34" />
                                <rdf:li rdf:resource="http://www.malariajournal.com/content/11/1/33" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.malariajournal.com/content/11/1/42">
        <title>An improved single-step lysis protocol to measure luciferase bioluminescence in Plasmodium falciparum</title>
        <description>This report describes the optimization and evaluation of a simple single-step lysis protocol to measure luciferase bioluminescence from genetically modified Plasmodium falciparum. This protocol utilizes a modified commercial buffer to improve speed of assay and consistency in the bioluminescence signal measured by reducing the manipulation steps required to release the cytoplasmic fraction. The utility of this improved assay protocol is demonstrated in typical assays that explore absolute and temporal gene expression activity.</description>
        <link>http://www.malariajournal.com/content/11/1/42</link>
                <dc:creator>Sandra Hasenkamp</dc:creator>
                <dc:creator>Eleanor Wong</dc:creator>
                <dc:creator>Paul Horrocks</dc:creator>
                <dc:source>Malaria Journal 2012, null:42</dc:source>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-42</dc:identifier>
                                    <dc:description>Optimized method to do luciferase assays with P. falciparum blood stage cultures. The presented method is simpler and removes a lot of the variation observed with the standard assay.</dc:description>
                <prism:require>/content/figures/1475-2875-11-42-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2012-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/41">
        <title>Using CF11 cellulose columns to inexpensively and effectively remove human DNA from Plasmodium falciparum-infected whole blood samples</title>
        <description>Background:
Genome and transcriptome studies of Plasmodium nucleic acids obtained from parasitized whole blood are greatly improved by depletion of human DNA or enrichment of parasite DNA prior to next-generation sequencing and microarray hybridization. The most effective method currently used is a two-step procedure to deplete leukocytes: centrifugation using density gradient media followed by filtration through expensive, commercially available columns. This method is not easily implemented in field studies that collect hundreds of samples and simultaneously process samples for multiple laboratory analyses. Inexpensive syringes, hand-packed with CF11 cellulose powder, were recently shown to improve ex vivo cultivation of Plasmodium vivax obtained from parasitized whole blood. This study was undertaken to determine whether CF11 columns could be adapted to isolate Plasmodium falciparum DNA from parasitized whole blood and achieve current quantity and purity requirements for Illumina sequencing.
Methods:
The CF11 procedure was compared with the current two-step standard of leukocyte depletion using parasitized red blood cells cultured in vitro and parasitized blood obtained ex vivo from Cambodian patients with malaria. Procedural variations in centrifugation and column size were tested, along with a range of blood volumes and parasite densities.
Results:
CF11 filtration reliably produces 500 nanograms of DNA with less than 50% human DNA contamination, which is comparable to that obtained by the two-step method and falls within the current quality control requirements for Illumina sequencing. In addition, a centrifuge-free version of the CF11 filtration method to isolate P. falciparum DNA at remote and minimally equipped field sites in malaria-endemic areas was validated.
Conclusions:
CF11 filtration is a cost-effective, scalable, one-step approach to remove human DNA from P. falciparum-infected whole blood samples.</description>
        <link>http://www.malariajournal.com/content/11/1/41</link>
                <dc:creator>Meera Venkatesan</dc:creator>
                <dc:creator>Chanaki Amaratunga</dc:creator>
                <dc:creator>Susana Campino</dc:creator>
                <dc:creator>Sarah Auburn</dc:creator>
                <dc:creator>Oliver Koch</dc:creator>
                <dc:creator>Pharath Lim</dc:creator>
                <dc:creator>Sambunny Uk</dc:creator>
                <dc:creator>Duong Socheat</dc:creator>
                <dc:creator>Dominic Kwiatkowski</dc:creator>
                <dc:creator>Rick Fairhurst</dc:creator>
                <dc:creator>Christopher Plowe</dc:creator>
                <dc:source>Malaria Journal 2012, null:41</dc:source>
        <dc:date>2012-02-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-41</dc:identifier>
                                    <dc:description>Ddescribes a methodological advance in the purification of Plasmodium falciparum DNA and depletion of accompanying human DNA, to generate material sufficient for next-generation sequencing platforms</dc:description>
                <prism:require>/content/figures/1475-2875-11-41-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>41</prism:startingPage>
        <prism:publicationDate>2012-02-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/40">
        <title>Malaria transmission in Libreville: results of a one year survey</title>
        <description>Background:
In Gabon, vector transmission has been poorly studied. Since the implementation of the Roll Back malaria recommendations, clinical studies have shown a decline in the burden of malaria in Libreville, the capital city of Gabon. To better understand the transmission dynamic in Libreville, an entomological survey was conducted in five districts of the city.
Methods:
Mosquitoes were sampled by human landing collection during 1 year in five districts of Libreville: Alibandeng, Beausejour, Camp des Boys and Sotega. Mosquitoes were identified morphologically and by molecular methods. The Plasmodium falciparum circumsporozoite indices were measured by ELISA, and the entomological inoculation rates (EIR) were calculated for all areas. Molecular assessments of pyrethroid knock down resistance (kdr) and of insensitive acetylcholinesterase resistance were conducted.
Results:
A total of 57,531 mosquitoes were caught during 341 person-nights (161 person-nights indoor and 180 person-nights outdoor) among which, 4,223 were Anopheles gambiae s.l. The average Human Biting Rate fell from 15.5 bites per person during the rainy season to 4.7 during the dry season. The An. gambiae complex population was composed of An. gambiae s.s molecular form S (99.5%), Anopheles melas (0.3%) and An. gambiae s.s. form M (0.2%). Thirty-three out of 4,223 An. gambiae s.l. were found to be infected by P. falciparum (CSP index = 0.78%). The annual EIR was estimated at 33.9 infected bites per person per year ranging from 13 in Alibandeng to 88 in Sotega. No insensitive AChE mutation was identified but both kdr-w and kdr-e mutations were present in An. gambiae molecular form S with a higher frequency of the kdr-w allele (76%) than the kdr-e allele (23.5%).
Conclusion:
Malaria transmission in Libreville occurred mainly during the rainy season but also during the dry season in the five districts. Transmission level is high and seems to be very heterogeneous in the town. Interestingly, the highest EIR was recorded in the most central and urbanized quarter and the lowest in a peripheral area. The decrease of transmission usually seen from peri-urban areas to urban centers is probably more dependent of the socio-economic level of a quarter than of its location in the city. Urban malaria control programmes need to consider the socio economic level of an area rather than the location in the city in order to determine the areas most favourable to malaria transmission.</description>
        <link>http://www.malariajournal.com/content/11/1/40</link>
                <dc:creator>Jean Romain Mourou</dc:creator>
                <dc:creator>Thierry Coffinet</dc:creator>
                <dc:creator>Fanny Jarjaval</dc:creator>
                <dc:creator>Christelle Cotteaux</dc:creator>
                <dc:creator>Eve Pradines</dc:creator>
                <dc:creator>Godefroy Lydie</dc:creator>
                <dc:creator>Maryvonne Kombila</dc:creator>
                <dc:creator>Frederic Pages</dc:creator>
                <dc:source>Malaria Journal 2012, null:40</dc:source>
        <dc:date>2012-02-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-40</dc:identifier>
                                    <dc:description>Clinical studies have shown a decline in the burden of malaria in Libreville, the capital city of Gabon, but the characteristics of transmission are poorly known. It appears that the decrease of transmission seen inperi-urban areas is probably more dependent of the socio-economic level of a quarter than of its location in the city.</dc:description>
                <prism:require>/content/figures/1475-2875-11-40-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>40</prism:startingPage>
        <prism:publicationDate>2012-02-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/39">
        <title>Combination of probenecid-sulphadoxine-pyrimethamine for intermittent preventive treatment in pregnancy</title>
        <description>The antifolate sulphadoxine-pyrimethamine (SP) has been used in the intermittent prevention of malaria in pregnancy (IPTp). SP is an ideal choice for IPTp, however, as resistance of Plasmodium falciparum to SP increases, data are accumulating that SP may no longer provide benefit in areas of high-level resistance. Probenecid was initially used as an adjunctive therapy to increase the blood concentration of penicillin; it has since been used to augment concentrations of other drugs, including antifolates. The addition of probenecid has been shown to increase the treatment efficacy of SP against malaria, suggesting that the combination of probenecid plus SP may prolong the useful lifespan of SP as an effective agent for IPTp. Here, the literature on the pharmacokinetics, adverse reactions, interactions and available data on the use of these drugs in pregnancy is reviewed, and the possible utility of an SP-probenecid combination is discussed. This article concludes by calling for further research into this potentially useful combination.</description>
        <link>http://www.malariajournal.com/content/11/1/39</link>
                <dc:creator>Julie Gutman</dc:creator>
                <dc:creator>S Patrick Kachur</dc:creator>
                <dc:creator>Laurence Slutsker</dc:creator>
                <dc:creator>Alexis Nzila</dc:creator>
                <dc:creator>Theonest Mutabingwa</dc:creator>
                <dc:source>Malaria Journal 2012, null:39</dc:source>
        <dc:date>2012-02-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-39</dc:identifier>
                                    <dc:description>This paper discusses the potential role of adding probenecid in improving SP efficacy in IPTp, thus potentially extending the lifespan of SP in its applications as the choice drug for for intermittent preventive treatment.</dc:description>
                <prism:require>/content/figures/1475-2875-11-39-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>39</prism:startingPage>
        <prism:publicationDate>2012-02-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/38">
        <title>High IFN-gamma and TNF production by peripheral NK cells of Colombian patients with different clinical presentation of Plasmodium falciparum   </title>
        <description>Background:
In Colombia, Plasmodium falciparum infection rarely results in severe disease or mortality compared to infections in African populations. During natural infection NK cells exhibit a cytolytic effect and regulate dendritic cells, macrophages, neutrophils as well as affect antigen specific T and B cell responses. To characterize the NK cells in P. falciparum infected patients of a highly endemic region of Colombia, the degree of NK proliferation and production of IFN gamma and TNF production in these cells were explored.
Methods:
Seventeen patients with acute and three with severe P. falciparum malaria patients from the Northwest region of the country were recruited in the study. In addition, 20 healthy controls were included: 10 from Medellin (no-transmission area) and 10 from the Uraba region (a malaria endemic area). Immunophenotypic analysis of peripheral mononuclear cells was performed by FACS to detect total number of NK cells, subtypes and intracellular IFNgamma and TNF production by NK cells in the different patient groups.
Results:
The total mean CD56+/CD3- NK cell proportions in acute and severe malaria subjects were 9.14% (7.15%CD56dim, 2.01%CD56bright) and 19.62% (16.05%CD56dim, 3.58%CD56bright), respectively, in contrast to healthy controls from endemic (total mean CD56+/CD3- 1.2%) and non-endemic area (total mean CD56+/CD3- 0.67%). Analysis of basal IFNgamma and TNF levels confirmed the CD56bright NK population as the main cytokine producer (p &lt; 0.0001) in the groups affected with malaria, with the CD56dim NK cell exhibiting the highest potential of TNF production after stimulus in the acute malaria group.
Conclusions:
The results confirm the important role of not only CD56bright but also of CD56dim NK cell populations as producers of the two cytokines in malaria patients in Colombia.</description>
        <link>http://www.malariajournal.com/content/11/1/38</link>
                <dc:creator>Olga Agudelo</dc:creator>
                <dc:creator>Julio Bueno</dc:creator>
                <dc:creator>Andres Villa</dc:creator>
                <dc:creator>Amanda Maestre</dc:creator>
                <dc:source>Malaria Journal 2012, null:38</dc:source>
        <dc:date>2012-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-38</dc:identifier>
                                    <dc:description>The paper adds to our knowledge of field-based, clinically oriented, NK cell subsets and cytokine production related  to malarial innate immunity.</dc:description>
                <prism:require>/content/figures/1475-2875-11-38-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>38</prism:startingPage>
        <prism:publicationDate>2012-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/37">
        <title>The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya</title>
        <description>Background:
Health facility stock-outs of artemether-lumefantrine (AL), the common first-line therapy for uncomplicated malaria across Africa, adversely affect effective malaria case-management. They have been previously reported on various scales in time and space, however the magnitude of the problem and trends over time are less clear. Here, 2010-2011 data are reported from public facilities in Kenya where alarming stock-outs were revealed in 2008.
Methods:
Data were collected between January 2010 and June 2011 as part of 18 monthly cross-sectional surveys undertaken at nationally representative samples of public health facilities. The primary monitoring indicator was total stock-out of all four weight-specific AL packs. The secondary indicators were stock-outs of at least one AL pack and individual stock-outs for each AL pack. Monthly proportions and summary means of the proportions over the monitoring period were measured for each indicator. Stock-out trends were assessed using linear regression.
Results:
The number of surveyed facilities across 18 time points ranged between 162 and 176 facilities. The stock-out means of the proportion of health facilities were 11.6% for total AL stock-out, 40.6% for stock-out of at least one AL pack, and between 20.5% and 27.4% for stock-outs of individual AL packs. Monthly decrease of the total AL stock-out was 0.005% (95% CI: 0.5 to +0.5; p = 0.983). Monthly decrease in the stock-out of at least one AL pack was 0.7% (95% CI: 1.5 to +0.3; p = 0.058) while stock-outs of individual AL packs decreased monthly between 0.2% for AL 24-pack and 0.7% for AL six-pack without statistical significance for any of the weight-specific packs.
Conclusions:
Despite lower levels of AL stock-outs compared to the reports in 2008, the stock-outs at Kenyan facilities during 2010-2011 are still substantial and of particular worry for the most detrimental:- simultaneous absence of any AL pack. Only minor decrease was observed in the stock-outs of individual AL packs. Recently launched interventions to eliminate AL stock-outs in Kenya are fully justified.</description>
        <link>http://www.malariajournal.com/content/11/1/37</link>
                <dc:creator>Raymond Sudoi</dc:creator>
                <dc:creator>Sophie Githinji</dc:creator>
                <dc:creator>Andrew Nyandigisi</dc:creator>
                <dc:creator>Alex Muturi</dc:creator>
                <dc:creator>Robert Snow</dc:creator>
                <dc:creator>Dejan Zurovac</dc:creator>
                <dc:source>Malaria Journal 2012, null:37</dc:source>
        <dc:date>2012-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-37</dc:identifier>
                                    <dc:description>A paper which helps to understand how supply is organized from central to peripheral level, and how this might affect the supply of peripheral units.</dc:description>
                <prism:require>/content/figures/1475-2875-11-37-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>37</prism:startingPage>
        <prism:publicationDate>2012-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/36">
        <title>Human Plasmodium knowlesi infection in Ranong province, southwestern border of Thailand</title>
        <description>Background:
Plasmodium knowlesi, a simian malaria parasite, has been reported in humans in many Southeast Asian countries. In Thailand, most of the limited numbers of cases reported so far were from areas near neighbouring countries, including Myanmar.
Methods:
Blood samples collected from 171 Thai and 248 Myanmese patients attending a malaria clinic in Ranong province, Thailand, located near the Myanmar border were investigated for P. knowlesi using nested PCR assays. Positive samples were also investigated by PCR for Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale, and were confirmed by sequencing the gene encoding the circumsporozoite protein (csp).
Results:
Two samples, one obtained from a Thai and the other a Myanmese, were positive for P. knowlesi only. Nucleotide sequences of the csp gene derived from these two patients were identical and phylogenetically indistinguishable from other P. knowlesi sequences derived from monkeys and humans. Both patients worked in Koh Song, located in the Kawthoung district of Myanmar, which borders Thailand.
Conclusion:
This study indicates that transmission of P. knowlesi is occurring in the Ranong province of Thailand or the Kawthoung district of Myanmar. Further studies are required to assess the incidence of knowlesi malaria and whether macaques in these areas are the source of the infections.</description>
        <link>http://www.malariajournal.com/content/11/1/36</link>
                <dc:creator>Natthawan Sermwittayawong</dc:creator>
                <dc:creator>Balbir Singh</dc:creator>
                <dc:creator>Mitsuaki Nishibuchi</dc:creator>
                <dc:creator>Nongyao Sawangjaroen</dc:creator>
                <dc:creator>Varaporn Vuddhakul</dc:creator>
                <dc:source>Malaria Journal 2012, null:36</dc:source>
        <dc:date>2012-02-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-36</dc:identifier>
                                    <dc:description>Plasmodium knowlesi infection in humans along the southwestern border of Thailand, including interesting discussion on the possible changes in epidemiology.</dc:description>
                <prism:require>/content/figures/1475-2875-11-36-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2012-02-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/35">
        <title>Human cerebral malaria and Plasmodium falciparum genotypes in Malawi</title>
        <description>Background:
Cerebral malaria, a severe form of Plasmodium falciparum infection, is an important cause of mortality in sub-Saharan African children. A Taqman 24 Single Nucleotide Polymorphisms (SNP) molecular barcode assay was developed for use in laboratory parasites which estimates genotype number and identifies the predominant genotype.
Methods:
The 24 SNP assay was used to determine predominant genotypes in blood and tissues from autopsy and clinical patients with cerebral malaria.
Results:
Single genotypes were shared between the peripheral blood, the brain, and other tissues of cerebral malaria patients, while malaria-infected patients who died of non-malarial causes had mixed genetic signatures in tissues examined. Children with retinopathy-positive cerebral malaria had significantly less complex infections than those without retinopathy (OR = 3.7, 95% CI [1.51-9.10]).The complexity of infections significantly decreased over the malaria season in retinopathy-positive patients compared to retinopathy-negative patients.
Conclusions:
Cerebral malaria patients harbour a single or small set of predominant parasites; patients with incidental parasitaemia sustain infections involving diverse genotypes. Limited diversity in the peripheral blood of cerebral malaria patients and correlation with tissues supports peripheral blood samples as appropriate for genome-wide association studies of parasite determinants of pathogenicity.</description>
        <link>http://www.malariajournal.com/content/11/1/35</link>
                <dc:creator>Danny Milner</dc:creator>
                <dc:creator>Jimmy Vareta</dc:creator>
                <dc:creator>Clarissa Valim</dc:creator>
                <dc:creator>Jacqui Montgomery</dc:creator>
                <dc:creator>Rachel Daniels</dc:creator>
                <dc:creator>Sarah Volkman</dc:creator>
                <dc:creator>Daniel Neafsey</dc:creator>
                <dc:creator>Daniel Park</dc:creator>
                <dc:creator>Stephen Schaffner</dc:creator>
                <dc:creator>Nira Mahesh</dc:creator>
                <dc:creator>Kayla Barnes</dc:creator>
                <dc:creator>David Rosen</dc:creator>
                <dc:creator>Amanda Lukens</dc:creator>
                <dc:creator>Daria Van Tyne</dc:creator>
                <dc:creator>Roger Wiegand</dc:creator>
                <dc:creator>Pardis Sabeti</dc:creator>
                <dc:creator>Karl Seydel</dc:creator>
                <dc:creator>Simon Glover</dc:creator>
                <dc:creator>Steve Kamiza</dc:creator>
                <dc:creator>Malcolm Molyneux</dc:creator>
                <dc:creator>Terrie Taylor</dc:creator>
                <dc:creator>Dyann Wirth</dc:creator>
                <dc:source>Malaria Journal 2012, null:35</dc:source>
        <dc:date>2012-02-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-35</dc:identifier>
                                    <dc:description>An interesting study confirming that the parasite genetic complexity is lower in cerebral malaria than in patients with non-complicated malaria. In their study, the authors found that cerebral malaria patients harbour a parasite population dominated by a single variant identical throughout the blood and organs.</dc:description>
                <prism:require>/content/figures/1475-2875-11-35-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>35</prism:startingPage>
        <prism:publicationDate>2012-02-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/34">
        <title>Anti-malarial drugs: how effective are they against Plasmodium falciparum gametocytes?</title>
        <description>Background:
Recent renewed emphasis on the eradication of malaria has highlighted the need for more tools with which to achieve this ambitious goal. One high priority area is the need to determine the gametocytocidal activity of both currently used anti-malarial drugs and those in the development pipeline. However, testing the activity of compounds against Plasmodium falciparum gametocytes is technically challenging both in vivo and in vitro.
Methods:
Here the use of a simple robust assay to screen a panel of currently used and experimental anti-malarial drugs against mature P. falciparum gametocytes is described.
Results:
Eight of 44 compounds tested reduced gametocyte viability by at least 50% and three showed IC50 values in nM range.
Conclusions:
There is a need to identify new compounds with activity against late stage gametocytes and the information provided by this in vitro assay is a valuable first step, which can guide future clinical studies.</description>
        <link>http://www.malariajournal.com/content/11/1/34</link>
                <dc:creator>Christopher Peatey</dc:creator>
                <dc:creator>Didier Leroy</dc:creator>
                <dc:creator>Donald Gardiner</dc:creator>
                <dc:creator>Katharine Trenholme</dc:creator>
                <dc:source>Malaria Journal 2012, null:34</dc:source>
        <dc:date>2012-02-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-34</dc:identifier>
                                <prism:require>/content/figures/1475-2875-11-34-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>34</prism:startingPage>
        <prism:publicationDate>2012-02-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.malariajournal.com/content/11/1/33">
        <title>Cytoadherence and virulence - the case of Plasmodium knowlesi malaria</title>
        <description>Background:
Cytoadherence of infected red blood cells to brain endothelium is causally implicated in malarial coma, one of the severe manifestations of falciparum malaria. Cytoadherence is mediated by specific binding of variant parasite antigens, expressed on the surface of infected erythrocytes, to endothelial receptors including, ICAM-1, VCAM and CD36. In fatal cases of severe falciparum malaria with coma, blood vessels in the brain are characteristically congested with infected erythrocytes. Brain sections from a fatal case of knowlesi malaria, but without coma, were similarly congested with infected erythrocytes. The objective of this study was to determine the binding phenotype of Plasmodium knowlesi infected human erythrocytes to recombinant human ICAM-1, VCAM and CD36.
Methods:
Five patients with PCR-confirmed P. knowlesi malaria were recruited into the study with consent between April and August 2010. Pre-treatment venous blood was washed and cultured ex vivo to increase the proportion of schizont-infected erythrocytes. Cultured blood was seeded into Petri dishes with triplicate areas coated with ICAM-1, VCAM and CD36. Following incubation at 37degreesC for one hour the dishes were washed and the number of infected erythrocytes bound/mm2 to PBS control areas and to recombinant human ICAM-1 VCAM and CD36 coated areas were recorded. Each assay was performed in duplicate. Assay performance was monitored with the Plasmodium falciparum clone HB3.
Results:
Blood samples were cultured ex vivo for up to 14.5 h (mean 11.3 +/- 1.9 h) to increase the relative proportion of mature trophozoite and schizont-infected red blood cells to at least 50% (mean 65.8 +/- 17.51%). Three (60%) isolates bound significantly to ICAM-1 and VCAM, one (20%) isolate bound to VCAM and none of the five bound significantly to CD36.
Conclusions:
Plasmodium knowlesi infected erythrocytes from human subjects bind in a specific but variable manner to the inducible endothelial receptors ICAM-1 and VCAM. Binding to the constitutively-expressed endothelial receptor CD36 was not detected. Further work will be required to define the pathological consequences of these interactions.</description>
        <link>http://www.malariajournal.com/content/11/1/33</link>
                <dc:creator>Farrah Fatih</dc:creator>
                <dc:creator>Angela Siner</dc:creator>
                <dc:creator>Atique Ahmed</dc:creator>
                <dc:creator>Lu Chan Woon</dc:creator>
                <dc:creator>Alister Craig</dc:creator>
                <dc:creator>Balbir Singh</dc:creator>
                <dc:creator>Sanjeev Krishna</dc:creator>
                <dc:creator>Janet Cox-Singh</dc:creator>
                <dc:source>Malaria Journal 2012, null:33</dc:source>
        <dc:date>2012-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1475-2875-11-33</dc:identifier>
                                    <dc:description>Another twist in the tale of cytoadherence ? Is in vitro cytoadherence really a marker of virulence, even in case of parasites, such as P. knowlesi or P. vivax, which are not normally sequestered ?</dc:description>
                <prism:require>/content/figures/1475-2875-11-33-toc.gif</prism:require>
                <prism:publicationName>Malaria Journal</prism:publicationName>
        <prism:issn>1475-2875</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>33</prism:startingPage>
        <prism:publicationDate>2012-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

